Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 185 Next >>

Filter Applied: adverse drug reaction (Click to remove)

Severe Myotonic Crisis Resembling Malignant Hyperthermia
Neurol 104:e213497, Wadhwani,A.R.,et al, 2025

Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990

Evidence-based guideline update: Treatment of Essential Tremor
Neurol 77:1752-1755, Zesiewicz, T.A.,et al, 2011

Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007

Syncope and Falls Due to Timolol Eye Drops
BMJ 332:960-961, Mller,M.E.,et al, 2006

Verapamil Induced Gingival Enlargement in Cluster Headache
JNNP 76:124-127, Matharu,M.S.,et al, 2005

Tetraparesis Associated with Colchicine is Probably Due to Inhibition by Verapamil of the P-glycoprotein Efflux Pump in the Blood-Brain Barrier
BMJ 331:513, Troger,U.,et al, 2005

Multifocal Myoclonus Due to Verapamil Overdose
Neurol 58:984-985, Vadlamudi,L.&Wijdicks,E.F.M., 2002

Asystole Induced by Edrophonium Following Beta Blockade
Neurol 57:739, Okun,M.S.,et al, 2001

Treatment of Postural Hypotension
JNNP 65:285-289, Mathias,C.J.&Kimber,J.R., 1998

Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997

Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995

Recurrent Migraine and Intravenous Immune Globulin Therapy
NEJM 329:583-584, Constantinescu,C.S.,et al, 1993

Parkinsonism Unmasked by Verapamil
Clinical Neuropharmacol 16:263-265, Garcia-Albea,E.,et al, 1993

Metoprolol-Induced Polymyalgia-Like Syndrome
Ann Int Med 114:96-97, Snyder,S., 1991

Exacerbation of Vasodepressor Syncope by Beta-Adrenergic Blockade
NEJM 324:1219-1220, Chan,W.L.,et al, 1991

Interactions Between Calcium Channel Blockers and the Anticonvulsants Carbamazepine and Phenytoin
Neurol 41:740-742, Bahls,F.H.,et al, 1991

Syncope and Presyncope Associated with Probable Adverse Drug Reactions
Arch Int Med 150:2309-2312, Hanlon,J.T.,et al, 1990

Cognitive Impairment Associated with Beta-Blockade in the Elderly
Postgrad Med J 66:1050-1052, Rogers,T.K.&Bowman,C.E., 1990

Neuropsychological Side Effects of B-Blockers
Arch Int Med 149:514-525, Dimsdale,J.E.,et al, 1989

Acute and Chronic Effects of Propranolol and Primidone in Essential Tremor
Neurol 39:1587-1588, Koller,W.C.&Vetere-Overfield,B., 1989

Beta-Blockers and Glucose Control
Drug Intell Clin Pharm 19:246-251, Mills,G.A.&Horn,J.R., 1985

Drug-Induced Seizures:A 10-Year Experience
Neurol 34:1582-1586, Messing,R.O.,et al, 1984

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023

NSAIDS, Hormonal Contraception, and Venous Thromboembolism, A Harmful Drug Interaction That Deserves More Attention
BMJ 382:p1990, Schmidt,M., 2023

Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021

Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021

Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020

Migraine
NEJM 383:1866-1876, Ashina, M., 2020

A young woman with symmetric weakness and behavioral disturbance
Neurol 90:e1442-e1447, Rosenberg, J.,et al, 2018

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014

Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013

Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012

Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010

Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010

Triptan Therapy in Migraine
NEJM 363:63-70, Loder,E., 2010

Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010

What if the sexual headache is not a joke?
BJMP 3:304-308, Redelman, M., 2010

Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009

Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009

Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009

Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008

Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008

Initial Management of Epilepsy
NEJM 359:166-176, French,J.A. &Pedley,T.A., 2008

Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008



Showing articles 0 to 50 of 185 Next >>